Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Abnormalities of Motor Imagery and Relationship With Depressive Symptoms in Mildly Disabling Relapsing-Remitting Multiple Sclerosis.
American Academy of Neurology Annual Meeting
Tysabri
Video game training enhances cognitive control in older adults.
Estimation of the effect of dalfampridine on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?
Microvesicles: novel biomarkers for neurological disorders.
Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
CHMP recommends granting a marketing authorization for Santhera's Raxone® for the treatment of Leber's Hereditary Optic Neuropathy (LHON)
Benign Multiple Sclerosis: Does it exist?
High-field imaging of neurodegenerative diseases.
Sustained disability improvement is associated with T1 lesion volume shrinkage in natalizumab-treated patients with multiple sclerosis.
Inhibition of Neuronal Degenerin/Epithelial Na+ Channels by the Multiple Sclerosis Drug 4-Aminopyridine.
Lodonal/LDN
Chronic inflammatory demyelinating polyneuropathy following malignant melanoma.
Optimizing parameter choice for FSL-Brain Extraction Tool (BET) on 3D T1-images in multiple sclerosis.
Lessons from Jack Griffin and the "pathogenesis of peripheral nerve disease".
Momenta Pharmaceuticals Announces CAFC Decision to Invalidate Remanded Teva Pharmaceuticals Patent in Daily COPAXONE(R) 20 mg Suit
A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone
Acute disseminated encephalomyelitis--a prospective study of clinical profile and in-hospital outcome predictors.
Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis.
DemTect, PANDA, EASY, and MUSIC: Cognitive Screening Tools with Age Correction and Weighting of Subtests According to Their Sensitivity and Specificity.
A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis.
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

Pages